Literature DB >> 17263005

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.

H Butzkueven1, J Chapman, E Cristiano, F Grand'Maison, M Hoffmann, G Izquierdo, D Jolley, L Kappos, T Leist, D Pöhlau, V Rivera, M Trojano, F Verheul, J P Malkowski.   

Abstract

Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional outcome studies in multiple sclerosis (MS) and has yielded invaluable epidemiological information. The World Wide Web now provides an excellent opportunity for an international, collaborative cohort study of MS outcomes. A web platform--MSBase--has been designed to collect prospective data on patients with MS. It is purely observational, enabling participating neurologists to contribute data on diagnosis, treatment and progress, to review anonymous aggregate data and to benchmark their patient population against other patient subsets or the entire dataset. MSBase facilitates collaborative research by allowing the online creation of investigator-initiated regional, national and international substudies. The registry aims to answer epidemiological questions that can only be addressed by prospective assessments of large patient cohorts. The registry is funded through the independent MSBase Foundation, and governed by an International Scientific Advisory Board. The MSBase Foundation commenced operations in July 2004 and since then, 22 neurologists from 11 countries have joined MSBase and are contributing 2400 patients to the total data pool.

Entities:  

Mesh:

Year:  2006        PMID: 17263005     DOI: 10.1177/1352458506070775

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  47 in total

1.  A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data.

Authors:  Tim Spelman; Orla Gray; Robyn Lucas; Helmut Butzkueven
Journal:  J Vis Exp       Date:  2015-12-09       Impact factor: 1.355

Review 2.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

Review 3.  Postmarketing evidence of disease-modifying drugs in multiple sclerosis.

Authors:  Maria Trojano; Damiano Paolicelli; Aurora Fuiani; Fabio Pellegrini; Pietro Iaffaldano; Vita Direnzo; Mariangela D'Onghia
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

4.  Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.

Authors:  Tim Spelman; Tomas Kalincik; Vilija Jokubaitis; Annie Zhang; Fabio Pellegrini; Heinz Wiendl; Shibeshih Belachew; Robert Hyde; Freek Verheul; Alessandra Lugaresi; Eva Havrdová; Dana Horáková; Pierre Grammond; Pierre Duquette; Alexandre Prat; Gerardo Iuliano; Murat Terzi; Guillermo Izquierdo; Raymond M M Hupperts; Cavit Boz; Eugenio Pucci; Giorgio Giuliani; Patrizia Sola; Daniele L A Spitaleri; Jeannette Lechner-Scott; Roberto Bergamaschi; François Grand'Maison; Franco Granella; Ludwig Kappos; Maria Trojano; Helmut Butzkueven
Journal:  Neurol Clin Pract       Date:  2016-04

5.  Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.

Authors:  Ian T Rossman; Jeffrey A Cohen
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

6.  SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Authors:  Riley Bove; Tanuja Chitnis; Bruce Ac Cree; Mar Tintoré; Yvonne Naegelin; Bernard Mj Uitdehaag; Ludwig Kappos; Samia J Khoury; Xavier Montalban; Stephen L Hauser; Howard L Weiner
Journal:  Mult Scler       Date:  2017-08-29       Impact factor: 6.312

7.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

8.  Cerberus, an Access Control Scheme for Enforcing Least Privilege in Patient Cohort Study Platforms : A Comprehensive Access Control Scheme Applied to the GENIDA Project - Study of Genetic Forms of Intellectual Disabilities and Autism Spectrum Disorders.

Authors:  Pierre Parrend; Timothée Mazzucotelli; Florent Colin; Pierre Collet; Jean-Louis Mandel
Journal:  J Med Syst       Date:  2017-11-16       Impact factor: 4.460

9.  Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis.

Authors:  Jordana Hughes; Vilija Jokubaitis; Alessandra Lugaresi; Raymond Hupperts; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Francois Grand'Maison; Pierre Grammond; Patrizia Sola; Diana Ferraro; Cristina Ramo-Tello; Maria Trojano; Mark Slee; Vahid Shaygannejad; Cavit Boz; Jeanette Lechner-Scott; Vincent Van Pesch; Eugenio Pucci; Claudio Solaro; Freek Verheul; Murat Terzi; Franco Granella; Daniele Spitaleri; Raed Alroughani; Jae-Kwan Jun; Adam Fambiatos; Anneke Van der Walt; Helmut Butzkueven; Tomas Kalincik
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

10.  Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Authors:  S Mahurkar; M Moldovan; V Suppiah; M Sorosina; F Clarelli; G Liberatore; S Malhotra; X Montalban; A Antigüedad; M Krupa; V G Jokubaitis; F C McKay; P N Gatt; M J Fabis-Pedrini; V Martinelli; G Comi; J Lechner-Scott; A G Kermode; M Slee; B V Taylor; K Vandenbroeck; M Comabella; F M Boneschi; C King
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.